Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Biomica Announces Participation at the 5th Microbiome Movement Drug Development Europe Conference on January 28-29, 2021 (Virtual Conference)
https://finance.yahoo.com/news/biomica-announces-participation-5th-microbiome-120000916.html
Wed, January 20, 2021, 2:00 PM
REHOVOT, Israel, Jan. 20, 2021 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), today announced it will be featured as a presenting company at the Microbiome Movement Drug Development Europe Conference. The conference is being held on January 28-29, 2021, virtually.
Dr. Elran Haber, Biomica's Chief Executive Officer, is scheduled to speak on the European Microbiome Leaders Panel during the morning opening plenary session on January 28 at 9:00 am CET.
The panel discussion will address current strategies to take microbiome-based therapeutics to market; the role of partnerships in future therapeutic strategies; what public institutions and regulators can do to support the microbiome sector; what tools can be utilized to reveal causation and molecular mechanisms of microbiome-based therapeutics; and where the industry is developing over the next five years.
Dr. Shiri Meshner, VP R&D of Biomica, will be presenting for the first time the positive and exciting results, as recently reported, from Biomica's pre-clinical trials in its immune-oncology program in her presentation titled: "From Computational Predictions to Preclinical Performance".
The presentation will be available after the conference.
To register as a participant of the conference see https://microbiome-europe.com/
low 5.00's especially if these additional 5 million shares start hitting the market.
I'm still under my average price thank goodness.
RSI on the daily still at 67 might settle in the 50's first and have a nice healthy reset.
$EVGN
BNGO doesn’t seem to be affected. If it drops low enough will buy some more today.
Midas the sector is being brought down by the downgrade today by gene editing bell weather EDIT.
Morgan Stanley Downgrades Editas Medicine to Underweight, Lowers Price Target to $45 January 19, 2021
2021-01-19 11:42:00 GMT DJ Editas Medicine Price Target Cut to $45.00/Share From $64.00 by Morgan Stanley
almost 50% cut in the price of a company well funded with almost a half billion in cash.
could see the millions of shares hit the market at any time from the 28 million dollar raise last week.
EVGN From their SEC filing, looks like the offering will be made at $5.22.
"Assuming that an aggregate of 5,363,984 shares are sold at a price of $5.22 per share, the last reported sale price of our ordinary shares on Nasdaq on January 12, 2021."
This sucks holding 100k shares market futures are surging and the where down. going back to sleep.
$EVGN
$EVGN You'll have to be comfortable with big pullbacks in order to see even bigger gains. The bias is towards to upside here. Since the march low we've seen an 8x increase in SP, even with a 55% pullback. The slow building volume and $ARKG holding is what will propel this company into the future. Staying long and strong for at least this year, maybe longer.
100k shares strong...
will make millions here.
why isn't this holding? Are people worried due to the political uncertainty armed protest in 50 states this weekend and then the inauguration transition. Maybe investors are spooked and going into cash until the transition is complete must be it.
$EVGN
Add all you can under $7.00
so many catalyst on the biotech, green agriculture & cannabis fronts.
Gaining momentum, solid technical breakout ahead.
quiet name primed to go parabolic. $10.00+ next week.
$EVGN
7+ in sight!
$EVGN
Boomage!!!
hold your shares for life changing gains!!
you snooze you lose.
always early this will be $20.00 sooner than later.
this is a multibillion dollar market cap in the making cathie wood of ARKG ETF gets behinds winners..
major catalysts coming. I said it before and I will say it one more time buy all you can under $7.00
$100.00 stock potential Beam and edit went from the teens to $100.00 plus in a few month early trials. EVGN has blockbuster product coming early next year.
Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders
$EVGN
$7.00+ is in the cards today they just got more cash. Looking for ARKG to buy more soon watch and learn how this works. We just broke new highs and a 5 year high yesterday. This chart is just starting to launch
EVGN under the radar name gearing up for double digit dollars stock will be explosive soon.
70 million cash no debt.
a product commercially ready early next year that will take massive market share from Monsanto roundup a green friendly product.
How Much Money Does Monsanto Make From Roundup:
How much money does Monsanto make from Roundup? In 2015, the company made nearly $4.76 billion in sales and $1.9 billion in gross profits
EVGN is a leading computational biology gene editing AI company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform.
EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.
1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf
Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.
Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html
Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders
$EVGN
Thanks just bought another 2k pre market she is going to run hard you can make book on that.
most undervalued gene editing platform AI computational application for green industrial & green agriculture including cannabis, fruits vegetables insects. And Biotech
Biotech subsidiary Biomica
Proof of concept, first-in-man study – Immuno-oncology program.
https://www.biomicamed.com/
EVGN Biomica microbiome-based therapeutics for immunology looks superior to Seres Therapeutics technology 2.5 billion company that went from 2.52-38.00
Seres therapeutics 2.4 billion market cap.
EVGN Biomica 200 million market cap.
EVGN has the superior tech look for a monster move into double digit dollars coming soon.
https://www.evogene.com/
EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.
1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf
Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.
Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html
Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders.
$EVGN
EVGN trades in TASE (Tel-Aviv Stock Exchange)
Sunday thru Thursday inclu.
Fri & Sat TASE closed.
Your quote is end trade Thursday in TASE.
The market leader is in the Naz due to the
average larger volume in any single day.
don't get scared or robbed for your shares.
I bought VTGN at .79 in December they did a raise at .92 it surged to $2.50 days later
company has many catalyst and hammers that are about to drop.
70 million in cash no debt commercial product hitting the market in 2022 massive revenue generator.
EVGN 52 week high & multi year high was made $6.49 yesterday.EVGN is going way higher!!
https://www.evogene.com/
get ready for liftoff!
double digits are coming.
green friendly revenue generating weed killer product next year to rival Monsanto which makes from Roundup? In 2015, the company made nearly $4.76 billion in sales and $1.9 billion in gross profits ...
only 40 million shares insiders & institutions like ARKG (cathie Wood & cantor fitzgerald own close to 50% the shares. high demand and low supply for these shares savvy investors are accumulating.
if you sold your shares call the police you have been robbed.
EVGN is a wealth creator at these levels. has 1000% ROI in the next year. Cathie Wood from ARK ETF owns it gene editing AI platform across many industries including biotech, agriculture & industrial
Cathie Wood ARKG ETF she picked Beam EDIT PACB gene editing stocks this one is going to exponentially grow and scale in share price and the EVGN has applications for biotech green agriculture and cannabis markets. This has 1000% upside potential by the end of the year.
EVGN is a leading computational biology gene editing AI company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform.
EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.
1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf
Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.
Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html
Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders
$VTGN
EVGN up big in Israel
https://finance.yahoo.com/quote/EVGN.TA?p=EVGN.TA&.tsrc=fin-srch
Evogene Ltd. (EVGN.TA)
Tel Aviv - Tel Aviv Price. Currency in ILA
1,910.00+281.00 (+17.25%)
$EVGN
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-240249
Prospectus Supplement
(To prospectus dated August 10, 2020)
$28,000,000
Ordinary Shares
We have entered into a Controlled Equity OfferingSM Sales Agreement, or sales agreement, with Cantor Fitzgerald & Co., or Cantor, relating to our ordinary shares, par value NIS 0.02 per share, offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the sales agreement, from time to time we may offer and sell ordinary shares having an aggregate gross sales price of up to $28,000,000 through Cantor, acting as sales agent, pursuant to this prospectus supplement and the accompanying prospectus.
Our ordinary shares are listed on the Nasdaq Stock Market, or Nasdaq, and the Tel Aviv Stock Exchange Ltd., or TASE, under the symbol “EVGN.” The last reported sale price of our ordinary shares on Nasdaq on January 12, 2021 was $5.22 per share.
Sales of our ordinary shares, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Subject to terms of the sales agreement, Cantor is not required to sell any specific number or dollar amounts of securities but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between Cantor and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.
Cantor will be entitled to compensation under the terms of the sales agreement at a fixed commission rate equal to 3% of the gross sales price per share sold. In connection with the sale of our ordinary shares on our behalf, Cantor will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of Cantor will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contributions to Cantor against certain civil liabilities, including liabilities under the Securities Act. See “Plan of Distribution.”
Investing in our securities involves risks. See “Risk Factors” beginning on page S-6 of this prospectus supplement and in the documents we incorporate by reference into this prospectus supplement and the accompanying prospectus.
Great news we just got 28 million from Canter Fitzgerald.
broke a 52 week high and multi year today!!
EVGN gets the upper hand here can sell when they want too this reminds me of another company that I invested in recently & then the share price flew 175%+. a few weeks later.
this company now has plenty of cash & no debt.
I just bought another 5k shares after hours under $6.00
will buy 10-20k more shares tomorrow in increments between $6.00-$7.00 before it blast off into double digits and beyond.
Cathie Wood ARKG ETF & Cantor Fitzgerald owns EVGN and expects exponential growth and scaling on multiple fronts from this cutting edge gene editing AI technology protocol.
EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.
1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf
Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html
Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders.
$EVGN
$28m offering and the stock barely moved. People don't wanna sell their gold! https://ih.advfn.com/stock-market/NASDAQ/evogene-EVGN/stock-news/84098521/prospectus-filed-pursuant-to-rule-424b5-424b5
EVGN pure unadulterated genius!!!
methodically adding up till $7.00
easy breezy $20.00+ can happen on a wide array updates on its gene editing AI platform that this company has in the EVGN
vast portfolio.
Cathie Wood ARKG owns EVGN and expects exponential growth and scaling on multiple fronts from this cutting edge technology protocol.
EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.
1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf
Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.
Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html
Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders.
$EVGN
Security EVGN / Evogene, Ltd. (M4119S104)
Industry Agricultural Chemicals
Institutional Owners 25
Shares Outstanding 36,491,379 shares
Institutional Shares 13,096,154 - 35.89% (ex 13D/G)
Institutional Value $ 46,153 USD ($1000)
Related IL:EVGN / Evogene Ltd (20 owners)
https://fintel.io/so/us/evgn
Buy all you can under $7.00
This can surge at a moments notice. Lots of updates from the company coming on all fronts oncology, green agriculture, green industrial.
billion dollar plus market cap in the making. only 220 million market cap.
double digit dollars are coming you can make book on that!
under the radar gem just getting noticed now.
35 million shares only half are owned by insiders and institutions like cathie wood of ARKG ETF Crispr gene editing plays backed by ARKG is where you want to be invested.
https://www.evogene.com/
EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.
1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf
Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing
Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html
EVGN biz presentation:
https://www.evogene.com/wp-content/uploads/2020/09/Evogene_Investor_PPT_Sep-2020_FINAL.pdf
Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 220 million market cap 35 million shares 45% owned by institutions & insiders
$EVGN
just warming up. Gene editing crispr
soon to be a parabolic runner as it continues its uptrend new 52 week highs today and on is way double digit dollars and beyond.
add to your stash and accumulate before it launches into a new orbit.
https://www.evogene.com/
EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.
1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf
Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.
Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html
Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders.
$EVGN
This is the Video that got me super interested and buying $EVGN
They use CRSPR tech in agriculture! $ARKG $CRSP $EDIT $SGMO $BEAM
https://www.linkedin.com/posts/evogene_agplenus-novel-mode-of-action-herbicide-activity-6744591094660657152-4qKy/
Day's Range 5.48 - 6.17
52 Week Range 0.75 - 6.17
Volume 1,210,976
Avg. Volume 1,422,504
$6.17 new 52w/h!
Float is way too small to handle the masses. Just the beginning.
my top pick for 2021
Cathie Wood discusses Genome gene editing stocks will become the next FANG stocks.
Great start here! Grabbed more this am!
$EVGN
Boom! Great call, nice DD!
EVGN 52 week high is coming up $6.00 then clear blue sky breakout...
https://www.evogene.com/
get ready for liftoff!
double digits are coming.
green friendly revenue generating weed killer product next year to rival Monsanto which makes from Roundup? In 2015, the company made nearly $4.76 billion in sales and $1.9 billion in gross profits ...
only 35 million shares insiders & institutions like ARKG (cathie Wood own close to 50% the shares. high demand and low supply for these shares savvy investors are accumulating.
if you sold your shares call the police you have been robbed.
EVGN is a wealth creator at these levels. has 1000% ROI in the next year. Cathie Wood from ARK ETF owns it gene editing AI platform across many industries including biotech, agriculture & industrial
Cathie Wood ARKG ETF she picked Beam EDIT PACB gene editing stocks this one is going to exponentially grow and scale in share price and the EVGN has applications for biotech green agriculture and cannabis markets. This has 1000% upside potential by the end of the year.
EVGN is a leading computational biology gene editing AI company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform.
EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.
1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf
Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing.
Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html
Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders
$EVGN
Make it a sticky post.
(I akready have one on)
Shark Bites: A Computational Predictive Biology Play
Upcoming catalyst are likely to put the stock on the radar screen of investors. $EVGN
By JAMES "REV SHARK" DEPORRE Jan 13, 2021 | 02:36 PM EST
Stocks quotes in this article: EVGN, ARKG
Evogene Ltd. (EVGN) is a small Israeli company that is using something called computational predictive biology to develop products in four different areas.
Computation Predictive Biology (CPB) is defined as "the development and application of data-analytical and theoretical methods, mathematical modeling and computational simulation techniques to the study of biological, ecological, behavioral, and social systems." More details can be found on Wikipedia.
EVGN believes that its CPB platform gives it a competitive edge that increases efficacy, reduces toxicity, cuts costs of development, and saves time. Forty of EVGN's 121 employees hold Ph.D.'s in a variety of disciplines.
EVGN has four subsidiaries, each with a different focus. The key areas of development are microbiome therapeutics, herbicides, pesticides, and medical cannabis.
This is obviously a highly complex business, but it is still quite small, and there are some upcoming catalysts that are likely to put the stock on the radar screen of investors.
One investor that already has discovered this stock is the Ark Genomic Revolution ETF (ARKG) , which was one of the top-performing ETFs in 2020. ARK is the largest investor in EVGN, and as of Jan. 12, 2021, held 4,583,323 shares of the 31.6 million that are outstanding.
The EVGN chart looks favorable as it consolidates in the $4.75-$5 area. I am looking to build this position further on any pullbacks.
Shark Bites: A Computational Predictive Biology Play
Upcoming catalyst are likely to put the stock on the radar screen of investors.
https://finance.yahoo.com/m/c5302400-16c8-3b81-8cf9-848a8858e044/shark-bites%3A-a-computational.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo
By JAMES "REV SHARK" DEPORRE Jan 13, 2021 | 02:36 PM EST
Stocks quotes in this article: EVGN, ARKG
Evogene Ltd. (EVGN) is a small Israeli company that is using something called computational predictive biology to develop products in four different areas.
Computation Predictive Biology (CPB) is defined as "the development and application of data-analytical and theoretical methods, mathematical modeling and computational simulation techniques to the study of biological, ecological, behavioral, and social systems." More details can be found on Wikipedia.
EVGN believes that its CPB platform gives it a competitive edge that increases efficacy, reduces toxicity, cuts costs of development, and saves time. Forty of EVGN's 121 employees hold Ph.D.'s in a variety of disciplines.
EVGN has four subsidiaries, each with a different focus. The key areas of development are microbiome therapeutics, herbicides, pesticides, and medical cannabis.
This is obviously a highly complex business, but it is still quite small, and there are some upcoming catalysts that are likely to put the stock on the radar screen of investors.
One investor that already has discovered this stock is the Ark Genomic Revolution ETF (ARKG) , which was one of the top-performing ETFs in 2020. ARK is the largest investor in EVGN, and as of Jan. 12, 2021, held 4,583,323 shares of the 31.6 million that are outstanding.
The EVGN chart looks favorable as it consolidates in the $4.75-$5 area. I am looking to build this position further on any pullbacks.
Float is way too small to handle the masses. Just the beginning.
Momentum building up. very high demand and very little supply only 35 million shares insiders & institutions like ARKG own over 45% of the shares.
All time high of $6.00 is pennies away then we go into uncharted territory.
this can double or triple in a blink of an eye. Quality name you want to hold for mind numbing gains.
always early..
Cathie Wood ARKG ETF picked Beam EDIT PACB gene editing stocks this one is going to exponentially grow and scale in share price and the applications for biotech green agriculture and weed markets. This has 1000% upside potential by the end of the year.
EVGN is a leading computational biology gene editing AI company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform.
EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.
1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf
Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing
Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html
Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders
EVGN website:
https://www.evogene.com/
Boomage Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
https://mma-user-upload.mixedmartialarts.com/2020-09/tenor%20(8).gif
$EVGN
Let's Roll!
$EVGN
$OEG
$NNDM
$BFT
Don't let these clowns MM steal your shares shorts will be taken to cleaners here you can make book on that.
once you buy your shares lock and key them GTC sky high.
This has a green tech angle to it. do your DD first product hits the market in 2022 with massive revenue potential. A green friendly product that will take profits & market share from Monsanto Roundup product that had 6 billion in sales 2 billion in profits. Also a Cannabis angle. And a next level immunology platform all built on a next level gene editing & AI platform that Cathie Wood from ARKG ETF loves and sees this company scaling and exponential growth on multiple fronts
EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.
1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf
Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 195 million market cap 35 million shares 45% owned by institutions & insiders
https://www.evogene.com/
$EVGN
EVGN under the radar name gearing up for new highs, stock will be explosive soon.
EVGN showing solid strength, we should see a run to $6+ soon. then $10+ small float & owned by ARKG Cathie Wood
January 11th 2021 Global Agricultural Biotechnology Market Outlook 2020,Business Overview by 2027 Available in Latest Report Biomica, Evogene Ltd., Canonic ltd. , Bayer AG, Valent BioSciences LLC
The agricultural biotechnology business is anticipated to augment business germination in the projection period of 2020 to 2027 reckoning to USD 74.55 billion by 2027 expanding at an annual growth of 9.94% in the above-mentioned projection years.
This agricultural biotechnology market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on agricultural biotechnology market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Download Sample PDF Copy of Report https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-agricultural-biotechnology-market
The major players covered in the agricultural biotechnology market report are KWS SAAT SE & Co. KGaA, ChemChina, Corteva., Limagrain, MITSUI & CO., LTD., AgPlenus ltd., Biomica, Evogene Ltd., Canonic ltd., Bayer AG, Valent BioSciences LLC, Nufarm Limited, Marrone Bio Innovations., Performance Plants Inc., ADAMA Ltd. among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Focusing points in the report
Key trends in the market place
Major players and brands
Drivers and restrains of the market
Strategies of key players and product offerings
In-depth market segmentation
Global Agricultural Biotechnology Market Scope and Market Size
Agricultural biotechnology market is segmented on the basis of type, application, organism type, technology, and product. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
On the basis of type, agricultural biotechnology market is segmented into molecular diagnostics, molecular markers, tissue culture, vaccines, genetic engineering, and others.
On the basis of application, the agricultural biotechnology market is bifurcated into transgenic crops, flower culturing, nutritional supplements, biofuels, antibiotic development, vaccine development and others.
On the basis of organism type, the agricultural biotechnology market is divided into plants, animals, microbes, and others.
On the basis of technology, the agricultural biotechnology market is fragmented into genome editing tools, ribonucleic acid interference [RNAi], biochips, deoxy ribonucleic acid [DNA] sequencing, and synthetic biology.
Based on the product, the agricultural biotechnology market is segregated into crop protection products, transgenic seeds, and synthetic biology-enables products. Crop protection products are further sub-categorized into biostimulants, and biopesticides. Transgenic seeds are further sub-segmented into soybean, fruits & vegetables, maize, cotton, and others.
Inquiry For Customize Report With Discount At https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-agricultural-biotechnology-market
Drivers:Global Agricultural Biotechnology Market
Escalated penetration of biotechnology, tissue culture, and molecular breeding and unique plant breeding is defining the success parameters of agricultural biotechnology market.
Agricultural biotechnology market is flourishing exponentially owing to the advancement of agriculture sciences this factor is driving the market growth.
Increment in the production and breeding of transgenic crop because of rising food demand from the consumer end is helping the agricultural biotechnology market to grow. Implementation of biotechnology tools to enhance the production value in terms of size, color, or yield of crops by modifying their traits is catering a potential market base for agricultural biotechnology business.
Adoption of biofuels and quality food demand which is free from pesticides or insecticides constituents is helping the agricultural biotechnology market a good volume of revenue and stock shares, in the developed and emerging pockets of farming countries. These certain values are driving the market growth of agricultural biotechnology market in the anticipated time phase of 2020 to 2027.
During the seven years period of business, agricultural biotechnology market is exposed to face some restraints and curbing factors such as dearth of adoption of such products by consumer base due to scarcity of knowledge, stringent regulations by government for modified crops. These parameters may impact the market growth. The upcoming technological advancements centrally focused upon producing quality crops and widening penetration of biotech-crop tactics in agriculture industry will help in to overcome the mentioned challenges.
Important Points Covered in Agricultural Biotechnology Market Report Are:
Study Coverage
Executive Summary
Breakdown Data by Manufacturers
Breakdown Data by Product
Breakdown Data by End User
Breakdown Data by Countries
Agricultural Biotechnology Market Opportunities, Challenges, Risks and Influences Factors Analysis
Company Profiles
Future Forecast (2020-2027)
Value Chain and Sales Channels Analysis
Research Findings and Conclusion
And More.
To know more about the studyhttps://www.databridgemarketresearch.com/reports/global-agricultural-biotechnology-market
Customization Available: Global Agricultural Biotechnology Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.
About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. Get Customization and Discount on Report by emailing sopan.gedam@databridgemarketresearch.com . We are content with our glorious 99.9 % client satisfying rate.
Contact:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email: Corporatesales@databridgemarketresearch.com
https://ksusentinel.com/2021/01/11/global-agricultural-biotechnology-market-outlook-2020business-overview-by-2027-available-in-latest-reportbiomica-evogene-ltd-canonic-ltd-bayer-ag-valent-biosciences-llc/
EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.
1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf
Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 195 million market cap 35 million shares 45% owned by institutions & insiders
https://www.evogene.com/
$EVGN
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
248
|
Created
|
11/21/13
|
Type
|
Free
|
Moderators |
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Application segment develops enhanced castor bean seeds to serve as a feedstock source for biofuel and other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and multi drug resistant organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
http://www.evogene.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |